Objectives To determine the diagnostic performance of MR elastography (MRE) and compare it with serum CA19-9 in differentiating malignant from benign pancreatic masses, with emphasis on differentiating between pancreatic ductal adenocarcinoma (PDAC) and mass-forming pancreatitis (MFP). Methods We performed a prospective, consecutive, 24-month study in 85 patients with solid pancreatic masses confirmed by histopathologic examinations. The mass stiffness and stiffness ratio (calculated as the ratio of mass stiffness to the parenchymal stiffness) were assessed. The diagnostic accuracy was analysed by calculating the area under the ROC curve (AUROC). Results The final diagnosis included 54 malignant tumours (43 patients with PDAC) and 31 benign masses (24 patients with MFP). The stiffness ratio showed better diagnostic performance than the mass stiffness and serum CA19-9 for the differentiation between malignant and benign masses (AUC: 0.912 vs. 0.845 vs. 0.702; P = 0.026, P < 0.001) and, specifically, between PDAC and MFP (AUC: 0.955 vs. 0.882 vs. 0.745; P = 0.026, P = 0.003). The sensitivity, specificity, and accuracy of stiffness ratio for the differentiation of PDAC and MFP were all higher than 0.9. Conclusions MRE presents an effective and quantitative strategy for non-invasive differentiation between PDAC and MFP based on their mechanical properties. Key Points • 3D MRE is useful for calculating stiffness of solid pancreatic tumours.
Introduction
Solid pancreatic masses, which cover a wide spectrum of pancreatic anomalies, can be classified as benign lesions (e.g., mass-forming pancreatitis [MFP] , lipoma, hamartoma, fibroma and solid pseudo-papillary neoplasm [SPN] ) or malignant neoplasms (e.g., pancreatic cancer, metastatic tumour, primary pancreatic lymphoma and neuroendocrine pancreatic tumour [NEPT] ) [1] [2] [3] [4] . Pancreatic ductal adenocarcinoma (PDAC), which accounts for 85-90% of all malignant pancreatic tumours, is one of the five most lethal malignancies worldwide [5] . Currently, its early detection is essential for complete R0 surgical resection (defined as resection for cure or complete remission), which is believed to be the best curative option for improving prognosis [6] . Differentiation between PDAC and MFP remains challenging because of significant overlap in radiological findings (e.g., focal solid mass around the head of the pancreas, double duct obstruction, and absence of hypervascularity) [7] [8] [9] [10] , and unless imaging shows definite features of malignancy, such as signs of vascular invasion or liver metastases, the diagnostic performance of conventional imaging remains inadequate for definitive differentiation between PDAC and MFP. Other solid pancreatic masses such as non-functioning NEPT and small SPNs are also prone to misdiagnosis as PDAC or other pancreatic malignancy [11] . Computed tomography (CT)-or endoscopic ultrasound (EUS)-guided biopsy can provide cytological samples for definitive diagnosis of pancreatic lesions. However, these procedures are invasive, the samples may not be sufficient, and the small, but not negligible risk of morbidity cannot be ignored [12] . Serum carbohydrate antigen 19-9 (CA19-9) may be useful for monitoring PDAC, but it is neither specific nor sensitive for initial diagnosis of PDAC, yielding both false negative results among patients without 1,4-fucosyltransferase enzyme activity and false positive results patients with non-malignant conditions including cholelithiasis, liver cirrhosis, and chronic pancreatitis [13, 14] .
Magnetic resonance elastography (MRE) is an MR-based technique that was developed for quantitative assessment of tissue stiffness based on mapping the propagation of shear waves in tissue [15] . MRE has been widely utilised to accurately stage hepatic fibrosis and to differentiate benign from malignant focal liver diseases [16] [17] [18] [19] [20] . Histologically, PDAC is a hard mass characterised by a marked desmoplastic reaction and build-up of fibrotic tissues [21] . MFP is also characterised by perilobular fibrosis, but with significantly lower mean collagen content compared with pancreatic carcinoma or tumour-associated chronic pancreatitis [22, 23] , which suggests that the stiffness of MFP should be less than that of PDAC [16, 21, 24, 25] . Previous elastography studies based on EUS have indicated that the stiffness ratio between tumour and surrounding parenchyma is a useful metric for differentiating solid pancreatic masses [26, 27] . Hence, we hypothesised that MRE assessment of both mass stiffness and the stiffness ratio would present an opportunity for differentiation of malignant from benign pancreatic masses, particularly PDAC from MFP, based on tissue mechanical information.
MR imaging using 40-Hz vibrations and a spin-echo echoplanar imaging (SE-EPI) pulse sequence with three dimensional (3D) motion encoding was recently shown to provide robust estimates of tissue shear stiffness in a healthy pancreas, presenting a better wave pattern and higher amplitude of motion when compared with imaging at 60 Hz [28] . 3D SE-EPI MRE acquisition and stiffness calculation algorithm is designed for application to small and/or geometrically complex organs, including the pancreas, brain, and breast [15, 28] . To our knowledge, no study has been conducted to evaluate the usefulness of 3D SE-EPI MRE for differentiation of solid pancreatic masses. Thus, the purpose of our study was to determine the diagnostic performance of 3D SE-EPI MRE and compare it with serum markers (CA19-9) in differentiating malignant from benign masses, with emphasis on the differential diagnosis between PDAC and MFP.
Materials and methods

Subjects
A prospective, consecutive, 24-month study was designed to assess the clinical performance of MRE-measured pancreatic stiffness in the differential diagnosis of solid pancreatic masses. The study was approved by the local institutional review board and conducted in accordance with the Declaration of Helsinki and its amendments, and Good Clinical Practice guidelines. The nature of MRE was explained in detail and written informed consent was obtained from all subjects.
Patient group: Consecutive patients suspected of having solid pancreatic masses based on CT/MR/ultrasound results in the local department of Radiology and Ultrasound from December 2013 to December 2015 were recruited. Two hundred and fifty-four patients were enrolled, and 169 were excluded ultimately based on the criteria described in the flow diagram ( Fig. 1) ) were recruited from the nearby community as controls during the study period, compiling the stiffness of the healthy pancreas. None of the healthy volunteers had history of pancreatic disease, symptoms of maldigestion, history of alcohol or tobacco abuse [29] , or increased serum levels of pancreatic enzymes.
Image acquisition
All examinations were performed on an MR scanner (Signa HDX 3.0T system; GE Healthcare, Milwaukee, WI, USA) equipped with an eight-channel phased-array body coil. All subjects were instructed to fast for 2 to 3 hours before the examination. An ergonomic soft pancreatic MRE passive driver [28] was placed against the upper abdomen, centred on the xiphisternum, and secured with a 20-cm-wide elastic band that wrapped around the body to ensure good coupling between the driver and the body. External mechanical shear waves, 40 Hz, were generated using an active acoustic actuator located outside the MR scanner room and were introduced into the upper abdomen via a 5-m flexible vinyl tube terminating in the passive driver, as described in literature [28] . All subjects were imaged in a supine position, feet first, with a 32-slice, flow-compensated, SE-EPI pulse sequence modified to include additional MRE motion-encoding gradients (MEGs) alternating in positive and negative x, y, and z directions to record full-vector tissue motion into the phase of the MR images. The acquisitions were performed at the end of expiration during 5 periods of suspended respiration (4 × 22 s and 1 × 11 s). The imaging parameters for 3D SE-EPI MRE were as follows: repetition time/echo time = 1375/38.8 ms; phase offsets = 3; field of view = 32 to 38 cm; acquisition matrix = 96 × 96; parallel imaging acceleration factor = 3; slice thickness = 3 to 3.5 mm; in-plane resolution = 3.3 × 3.3 mm to 3.9 × 3.9 mm. We also performed axial T1-and T2-weighted scans with/without fat suppression and coronal scans. The imaging parameters are given in Supplementary Table 1. A comfort scale rating of the MRE exam was subsequently obtained based on patient experience. Each patient completed a questionnaire, scoring the test for comfort and acceptance level on a scale of 1 (intolerable) to 5 (very satisfactory).
Image analysis
The post-processing software was supplied by the Mayo Clinic, Rochester, MN, USA, along with the MRE pulse sequence. The acquired wave images were processed automatically on the scanner to generate quantitative images depicting tissue stiffness maps (elastograms) using the inversion algorithm previously described for a healthy pancreas [28] . A 3D direct inversion of the Helmholtz wave equation using the curl of the measured wave fields and 3D directional filtering were performed to generate elastograms from the wave images. MR magnitude images were also obtained from the MRE images, showing anatomical information co-registered with the wave images and elastograms to be used for localisation of anatomical features. Regions of interest (ROIs) were drawn on the Fig. 1 Flowchart shows the study enrolment process during the 24-month study period magnitude images to encompass as much of the mass as possible while avoiding the borders to reduce boundary effects. The ROIs were transferred to the elastograms to obtain the tissue stiffness (i.e., tissue elasticity modulus) in the units of kilopascals. Image slices containing the mass were selected in a slice-by-slice fashion with one ROI for each slice and mean stiffness of each mass was calculated as the average of the stiffness values from the pooled slices containing the mass. The stiffness of extra-lesional pancreatic parenchyma was calculated by averaging the stiffness from 2 to 3 ROIs (one ROI for each slice, >300 mm 2 ) in the parenchyma across its largest dimension in 2 to 3 consecutive slices, away from mass, borders, and large vessels. ROIs in both masses and parenchyma were oval or geographic in shape. The stiffness ratio was calculated as the stiffness of the pancreatic mass/the stiffness of the pancreatic parenchyma.
The MRE images were interpreted by a primary reader (4 years of experience interpreting MRE) and a secondary reader (2 years of MRE experience) who were not aware of the final diagnosis of the solid masses. Stiffness measurements were performed twice, with an interval of at least 4 weeks between evaluations to avoid memory bias. Intra-and inter-reader agreements were calculated, and after testing the reproducibility of the stiffness measurement, the results from the primary reader were utilised for all subsequent analysis.
Histopathologic assessment
The median interval between surgery/biopsy and MR examinations was 4 days (range 1 to 21 days), and in 80 patients (94.1%), the interval was ≤7 days. FNA or surgical specimens were examined by staining with haematoxylin/eosin (H&E) and by immunohistochemistry for cytokeratin, CD56, chromogranin, and synaptophysin for neuroendocrine tumours, thyroid transcription factor-1 for lung cancer, cytokeratin 20, villin, and CDX-2 for colon cancer, and β-catenin, AACT, vimentin, synaptophysin, cytokeratin, and ki67 for SPN. The histopathologic analysis was performed in consensus by two experienced pathologists with 17 and 12 years of experience in tumour pathology who were blinded to the results of MRE or other radiological assessments.
Statistical analysis
Continuous variables were analysed for normality using the Shapiro-Wilk test, and values (age, body mass index, and mass size) showing a normal distribution are expressed as means (±SD) and data showing non-normal distribution (stiffness measurements in different groups) are expressed as the median with 25th and 75th percentiles of the interquartile range (IQR). Statistical comparisons were performed using the Student's t test (age and BMI between control and patient groups) or the Kruskal-Wallis H test with post-hoc Dunn's multiple comparisons test (mass stiffness, stiffness ratio, and pancreatic parenchymal stiffness values among different groups), as appropriate. Categorical variables are expressed as counts and percentages. The chi-squared test (χ 2 test) was used to compare gender between control and patient groups. Intra-and inter-reader agreement were assessed using the intra-class correlation coefficient (ICC). Receiver operating characteristic (ROC) curve analyses were used to compare the diagnostic performance of mass stiffness, stiffness ratio, and CA19-9 for differentiation between malignant (PDAC, metastatic tumour, and NEPT) and benign masses (MFP, lipoma, and SPN) and between PDAC and MFP. The area under the ROC curve (AUC), accuracy, sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) were then calculated. Comparisons of AUCs were done using the method proposed by DeLong et al. [30] . Sensitivity, specificity, and accuracy were compared based on the McNemar test [31, 32] . Statistical analyses were performed with the commercially available SPSS Version 16.0J package (SPSS Inc, Chicago, IL, USA) and Graphpad Prism Continuous data are presented as median (25th-75th percentiles) or mean ± standard deviation. TBIL total bilirubin; DBIL direct bilirubin; FBG fasting blood glucose 6.0 (GraphPad Software Inc, La Jolla, CA, USA). ROC curves and ROC curve comparisons were obtained with MedCalc software (MedCalc Software, Mariakerke, Belgium). P < 0.05 indicated a significant difference.
Results
Patients
The mean patient acceptance/comfort scores for MRE were 3.67 ±0.67 (patient group) and 4.05 ±0.60 (control group; P = 0.015). Except for four patients who were excluded because of severe back pain, possibly secondary to neural invasion by a tumour at the pancreatic body/tail, there were no complications of MRE reported during the study. There were no significant differences in age (Student's t test, P = 0.251), gender (chi-squared test, P = 0.299), or BMI (Student's t test, P = 0.365) between the patient and the control groups. Among the 85 patients, 53 underwent surgical resection of masses and were diagnosed by post-resection histological evaluation and 32 patients were diagnosed by EUS-FNA biopsy (details are presented in the Supplementary Appendix).
Stiffness of solid pancreatic masses and pancreatic parenchyma
The stiffness measurements for the masses showed excellent inter-and intra- Mass stiffness, stiffness ratio, and parenchymal stiffness values for different subtypes of masses are shown in Table 2 and Fig. 5 . When comparing the mass stiffness in PDAD/MFP/metastasis/NEPT/SPN subtypes with normal pancreatic stiffness, the mass stiffness was significantly higher in each group except for SPN (Dunn's test, P < 0.001, 0.003, 0.031, 0.001, and 0.41 respectively). difference to those of MFP (both P > 0.999 for mass stiffness; P = 0.249, P > 0.999 for stiffness ratio, respectively).
The stiffness of the pancreatic parenchyma also showed significant variation among groups of different subtypes of masses (Kruskal-Wallis test, P < 0.001; Table 2 and Fig.  5c ). Pancreatic parenchymal stiffness was greatest in MFP (1.72 [1.40-2.02] kPa), followed by PDAC (1.45 [IQR: 1.24-1.57] kPa; Dunn's test, P = 0.479, without statistical significance) and then healthy pancreas (P < 0.001 and P = 0.002, respectively). Parenchymal stiffness in NEPT, metastatic tumour, and SPN was all similar to that of a healthy pancreas (Dunn's test, all P > 0.999). Table 3 summarises the performance of MRE vs. CA19-9 for differentiation between benign and malignant tumours and between PDAC and MFP, with the AUC plots shown in Fig.  6 . Stiffness ratio showed better diagnostic performance for differentiation between benign and malignant masses than either mass stiffness or serum CA19-9 (AUC: 0.912 vs. 0.845 vs. 0.702; P = 0.026 and P < 0.001, respectively) and between PDAC and MFP (AUC: 0.955 vs. 0.882 vs. 0.745; P = 0.026 and P = 0.003, respectively). The stiffness ratio also showed better sensitivity (88.9% vs. 68.5%, and 90.7% vs. 72.1%; both P < 0.001) than the mass stiffness in both tasks, while differences in specificity among the two measurements were not statistically significant (87.1% vs. 93.5%, and 95.8% vs. 95.8%; both P > 0.05).
Diagnostic performance
The optimal cut-off value for the stiffness ratio, 1.38, provided a sensitive and specific indicator for differentiating malignancy from benign masses and PDAC from MFP. Among the 67 patients with confirmed PDAC or MFP, the stiffness ratio had an overall accuracy of 92.5% (62/67). Four of 43 cases of PDAC and 1 of 24 MFP cases were mis-classified as the opposite category. Among all 85 pancreatic masses, 75 were correctly classified by the stiffness ratio for an overall accuracy rate of 88.2%. Four of 43 cases of PDAC, 1 of 24 cases of MFP, 2 of 7 cases of NEPT, and 3 of 6 cases of SPN were mis-classified.
Discussion
Our preliminary results on a 2-year prospective evaluation show that 3D SE-EPI MRE is well tolerated and feasible for assessing the mechanical properties for solid pancreatic masses. The diagnostic performance of the stiffness ratio was significantly better than either mass stiffness or serum CA19-9 level in differentiation of solid malignant tumours from benign masses and, specifically, in differentiating PDAC from MFP. Sensitivity, specificity, and accuracy of the stiffness ratio for differentiation of PDAC from MFP were all >0.9.
Our finding that serum CA19-9 had a high false negative rate (sensitivity 46.5%) for predicting PDAC at an optimised Fig. 3 A 56-year-old woman with pancreatic adenocarcinoma. a. Axial contrast-enhanced CT image shows an ill-defined hypodense mass in the uncinate process. b. The mass is slightly hyperintense or isointense in axial fat-saturated T2-weighted MR images. c. In the MRE elastogram, the lesion is much stiffer than the surrounding tissue (3.30 ±0.98 kPa vs. 1.37 ±0.33 kPa). d. Histological sections (haematoxylin-eosin stain, ×10) confirmed a moderately differentiated pancreatic adenocarcinoma Fig. 2 A 62-year-old man with mass-forming pancreatitis. a. Axial contrast-enhanced CT image shows an ill-defined isodense mass at the head of the pancreas. b. The mass appears almost isointense in axial T2-weighted MR images. c. In the elastogram, the lesion appears to be stiffer than the surrounding pancreatic parenchyma (2.43 ±0.48 kPa vs. 1.27 ±0.42 kPa). The placement of regions of interest (ROIs) is shown in both the tumour and pancreatic parenchyma, encompassing the mass and the parenchyma, excluding boundaries, large vessels, and surrounding tissues. d. Histological sections (haematoxylin-eosin stain, ×10) confirmed benign mass-forming pancreatitis cut-off value of 91 KU/L was in agreement with previous reports [13, 14] . The diagnostic performance of serum CA19-9 was inferior to that of the MRE diagnostic indices in our evaluation, and our results showed that the MRE stiffness ratio (sensitivity 90.7%, specificity 95.8%) had comparable sensitivity but greater specificity than that reported for contrast-enhanced CT/MRI (sensitivity 82 to 94% and specificity 75 to 83%) [33, 34] , and this result was comparable to the that of EUS elastography (sensitivity 100%, specificity 96.3%) [26, 35] . Microscopically, PDAC has obvious fibrous tissue infiltrating and enveloping the neoplasm [23] , which could account for greater stiffness than both normal pancreas and MFP. MFP with various degrees of fibrosis was also shown to be stiffer than a normal pancreas, and in some cases, overlapping the stiffness of PDAC, as shown both in our study and in previous EUS studies [36] . Since MFP always occurs in Continuous data are presented as medians (25th to 75th percentiles). PDAC pancreatic adenocarcinoma; MFP mass-forming pancreatitis; NEPT neuroendocrine pancreatic tumour; Met metastasis; SPN solid pseudo-papillary neoplasm. The p values were calculated by Kruskal-Wallis H tests (excluding the lipoma). By using post-hoc Dunn's multiple comparisons test, the following pairwise comparisons showed statistical difference: PDAC vs. MFP (P < 0.001) and PDAC vs. SPN (P = 0.039) for mass stiffness; PDAC vs. MFP (P < 0.001) and MFP vs. Met (P = 0.018) for stiffness ratio.
a background of chronic pancreatitis, which is expected to increase the referenced parenchymal stiffness, a change that would contribute to the lower stiffness ratio and tighter distribution of MFP and amplify its difference from PDAC. The parenchymal stiffness of PDAC is usually slightly higher than the normal pancreas, but not as high as MFP [37] . Thus, the diagnostic accuracy, sensitivity, and NPV were all improved when adopting stiffness ratio. EUS elastography has been demonstrated as a promising technique for the differentiation between benign and malignant pancreatic masses, showing excellent sensitivity ranging from 95% to 100% and variable specificity ranging from 67% to 92.9% [26, 36] . We found that the MRE stiffness ratio achieved a reasonable sensitivity (88.9%) and specificity (87.1%) in differentiating benign and malignant pancreatic tumours. The slightly inferior performance of the MRE stiffness ratio when compared to EUS elastography, and in differentiating all tumours (malignancy from benignancy) vs. PDAC from MFP can be explained by the wide range of stiffness values and the wide distribution of stiffness ratio in NEPT and SPN. Contrary to our results, NEPT and SPN showed a tight stiffness distribution at EUS elastography study [26] , which may have contributed to better diagnostic performance in their study (sensitivity 100%, specificity 92.9%). This discrepancy will require additional evaluation in larger patient populations in each group, which would also improve the statistical power and clarify the true diagnostic potential of both stiffness and the stiffness ratio. In contrast to EUS elastography, MRE is non-invasive, and we did not encounter compression or motion artefacts from the vibration of the deep-seated pancreas. ROIs can be accurately drawn to exclude non-mass-bearing tissues referencing magnitude images [28] and T2-weighted images, and MRE can be readily included in the standard pancreatic MRI protocol that is already in wide use in the management of patients with pancreatic disease. Hence, MRE can be recommended as a useful MR complementary sequence for differential diagnosis of solid pancreatic tumours. Cut-off values were selected based on receiver operating characteristic (ROC) analysis with greater stiffness/stiffness ratio in PDAC/malignancy. Numbers in parentheses are the 95% confidence interval. AUC area under the ROC curve; NPV negative predictive value; PPV positive predictive value This study has several limitations. Firstly, this is a singlecentre study and the sample size is relatively small, particularly in terms of the number of patients with NEPT, SPN, and metastatic masses, and solid pancreatic tumours are not fully represented. Secondly, the MRE technique has lower resolution than routine MRI. Although 3D SE-EPI MRE provides for clearer measurement of focal lesion stiffness and delineation of pancreatic and mass contour vs. 2D gradient-recalled echo MRE, estimates based on lower frequencies may be biased in small masses because the special resolution is lower at 40 Hz than at 60 Hz. In the future, true 3D imaging may help improve the resolution and accuracy of MRE for focal lesions.
In conclusion, our preliminary results suggest that 3D SE-EPI MRE may have clinical applications for obtaining tissue stiffness measurements independent of morphological findings for characterisation and differentiation of solid pancreatic tumours. MRE is a relatively quick, effective, and promising method for non-invasive evaluation of solid pancreatic tumours, particularly in cases of PDAC vs. MFP. We anticipate that our results will prompt further investigation in future studies.
